--Data supports MYCAPSSA® as non-inferior to long-acting injectable somatostatin receptor ligands (iSRLs)--
--Data demonstrated patients taking MYCAPSSA had significant improvement in acromegaly related symptoms and patient reported outcomes after switching from iSRLs--
https://finance.yahoo.com/news/chiasma-presents-positive-data-mycapssa-150000946.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.